In addition, the NICE guidelines state that only for women with BRCA1 mutations, the opposing effects of potentially increased risk of breast cancer versus lifetime protection against ovarian cancer by taking OC should be discussed [20]. This evidence concerns the gene BRCA1 and ovarian cancer.